Although we have validated that overexpression of FAM30A could inhibit the proliferation, invasion, and metastasis of CRC, and promote CRC cell apoptosis, much more experiments needed to explore whether FAM30A could be a novel therapeutic target and when and at what stage of colorectal cancer cases will it be administered and with what delivery system? This evidence concerns the gene FAM30A and colorectal carcinoma.